Showing 6 targets
GLP-1
MetabolicApproved Drug Exists
Market Leader
Semaglutide (Novo)
Oral Challenger
Orforglipron (Lilly)
KRAS
OncologyApproved Drug Exists
Market Leader
Sotorasib (Amgen)
RAS-ON
Revolution Medicines
B7-H3
OncologyRace to First
Frontrunner
Ifinatamab deruxtecan
Fast Follower
Vobramitamab duocarmazine
TL1A
I&IRace to First
Frontrunner
Tulisokibart (Merck)
Fast Follower
Afimkibart (Roche)
Cell Therapy
OtherRace to First
Frontrunner
Eli Lilly/Orna
Fast Follower
AbbVie/Capstan
VEGF-PD1 Bispecific
OncologyRace to First
Frontrunner
Ivonescimab (Summit/Akeso)
Fast Follower
HLX301 (Henlius)